Literature DB >> 17082316

Facilitating matched pairing and expression of TCR chains introduced into human T cells.

Jürgen Kuball1, Michelle L Dossett, Matthias Wolfl, William Y Ho, Ralf-Holger Voss, Carla Fowler, Philip D Greenberg.   

Abstract

Adoptive transfer of T lymphocytes is a promising treatment for a variety of malignancies but often not feasible due to difficulties generating T cells that are reactive with the targeted antigen from patients. To facilitate rapid generation of cells for therapy, T cells can be programmed with genes encoding the alpha and beta chains of an antigen-specific T-cell receptor (TCR). However, such exogenous alpha and beta chains can potentially assemble as pairs not only with each other but also with endogenous TCR alpha and beta chains, thereby generating alphabetaTCR pairs of unknown specificity as well as reducing the number of exogenous matched alphabetaTCR pairs at the cell surface. We demonstrate that introducing cysteines into the constant region of the alpha and beta chains can promote preferential pairing with each other, increase total surface expression of the introduced TCR chains, and reduce mismatching with endogenous TCR chains. This approach should improve both the efficacy and safety of ongoing efforts to use TCR transfer as a strategy to generate tumor-reactive T cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082316      PMCID: PMC1852191          DOI: 10.1182/blood-2006-05-023069

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  How much TCR does a T cell need?

Authors:  N Labrecque; L S Whitfield; R Obst; C Waltzinger; C Benoist; D Mathis
Journal:  Immunity       Date:  2001-07       Impact factor: 31.745

Review 2.  A listing of human tumor antigens recognized by T cells.

Authors:  N Renkvist; C Castelli; P F Robbins; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  2001-03       Impact factor: 6.968

3.  Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes.

Authors:  L J Cooper; M Kalos; D A Lewinsohn; S R Riddell; P D Greenberg
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

5.  Mechanisms contributing to T cell receptor signaling and assembly revealed by the solution structure of an ectodomain fragment of the CD3 epsilon gamma heterodimer.

Authors:  Z J Sun; K S Kim; G Wagner; E L Reinherz
Journal:  Cell       Date:  2001-06-29       Impact factor: 41.582

Review 6.  The specificity of TCR/pMHC interaction.

Authors:  Markus G Rudolph; Ian A Wilson
Journal:  Curr Opin Immunol       Date:  2002-02       Impact factor: 7.486

7.  The transmembrane adaptor protein TRIM regulates T cell receptor (TCR) expression and TCR-mediated signaling via an association with the TCR zeta chain.

Authors:  H Kirchgessner; J Dietrich; J Scherer; P Isomäki; V Korinek; I Hilgert; E Bruyns; A Leo; A P Cope; B Schraven
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

8.  Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.

Authors:  T Stanislawski; R H Voss; C Lotz; E Sadovnikova; R A Willemsen; J Kuball; T Ruppert; R L Bolhuis; C J Melief; C Huber; H J Stauss; M Theobald
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

Review 9.  T-cell-receptor gene therapy.

Authors:  Ton N M Schumacher
Journal:  Nat Rev Immunol       Date:  2002-07       Impact factor: 53.106

10.  Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.

Authors:  J Kuball; M Schuler; E Antunes Ferreira; W Herr; M Neumann; L Obenauer-Kutner; L Westreich; C Huber; T Wölfel; M Theobald
Journal:  Gene Ther       Date:  2002-07       Impact factor: 5.250

View more
  154 in total

1.  Mixed T cell receptor dimers harbor potentially harmful neoreactivity.

Authors:  Marleen M van Loenen; Renate de Boer; Avital L Amir; Renate S Hagedoorn; Gerdien L Volbeda; Roelof Willemze; Johannes J van Rood; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

Review 2.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

3.  T cell receptors and cancer: gain gives pain.

Authors:  Malcolm Brenner
Journal:  Nat Med       Date:  2010-05       Impact factor: 53.440

4.  Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies.

Authors:  Marleen M van Loenen; Renate de Boer; Renate S Hagedoorn; Esther H M van Egmond; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

5.  Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes.

Authors:  Michael S Bennett; Aviva Joseph; Hwee L Ng; Harris Goldstein; Otto O Yang
Journal:  AIDS       Date:  2010-11-13       Impact factor: 4.177

Review 6.  New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.

Authors:  Thomas M Schmitt; Ingunn M Stromnes; Aude G Chapuis; Philip D Greenberg
Journal:  Clin Cancer Res       Date:  2015-10-13       Impact factor: 12.531

Review 7.  Hitting the Target: How T Cells Detect and Eliminate Tumors.

Authors:  Anthony E Zamora; Jeremy Chase Crawford; Paul G Thomas
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 8.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 9.  Immunomodulation in the treatment of haematological malignancies.

Authors:  Michela Cesco-Gaspere; Emma Morris; Hans J Stauss
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

10.  Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

Authors:  Dyantha I van der Lee; Rogier M Reijmers; Maria W Honders; Renate S Hagedoorn; Rob Cm de Jong; Michel Gd Kester; Dirk M van der Steen; Arnoud H de Ru; Christiaan Kweekel; Helena M Bijen; Inge Jedema; Hendrik Veelken; Peter A van Veelen; Mirjam Hm Heemskerk; J H Frederik Falkenburg; Marieke Griffioen
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.